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Abstract 
For the first time, fully functional human mesenchymal stem cells (hMSCs) have been 
cultured at the litre-scale on microcarriers in a stirred-tank 5 l bioreactor, (2.5 l 
working volume) and were harvested via a potentially scalable detachment protocol that 
allowed for the successful detachment of hMSCs from the cell-microcarrier 
suspension. Over 12 days, the dissolved O2  concentration was > 45 % of 
saturation and the pH between 7.2 and 6.7 giving a maximum cell density in the 5 l 
bioreactor of 1.7 x 105  cells/ml; this represents >sixfold expansion of the hMSCs, 
equivalent to that achievable from 65 fully-confluent T-175 flasks. During this time, the 
average specific O2 uptake of the cells in the 5 l bioreactor was 8.1 fmol/cell h and, in 
all cases, the 5 l bioreactors outperformed the equivalent 100 ml spinner-flasks run in 
parallel with respect to cell yields and growth rates. In addition, yield coefficients, 
specific growth rates and doubling times were calculated for all systems. Neither the 
upstream nor downstream bioprocessing unit operations had a discernible effect on 
cell quality with the harvested cells retaining their immunophenotypic markers, key 
morphological features and differentiation capacity. 
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Introduction 
Regenerative medicine, of which cell-based therapies will play a significant role, has the 
potential to revolutionise the healthcare industry and replicate the success of the human 
therapeutic protein industry, which is currently valued at approximately UK£30 billion 
(Want et al. 2012).  For this to be achieved however, manufacturing platforms must be 
developed for the reproducible production of clinically-relevant numbers of anchorage-
dependent cells.  Until now, anchorage-dependent stem cells, including human 
mesenchymal stem cells (hMSCs), have mainly been cultured as a monolayer on two-
dimensional platforms such as tissue culture-treated plastic, including cell factories and 
roller bottles.  Although such methods are commonly used and considered reliable, they 
pose significant limitations with respect to scale-up. For clinical indications which will 
require lot sizes of billions, if not trillions of cells (Rowley et al. 2012), it is clear that 
these traditional two-dimensional expansion methods are unsuitable.  As such, other 
methods are being investigated (Want et al. 2012; Rowley et al. 2012) and a promising 
alternative is the usage of microcarrier-based systems in bioreactors.   
 
Microcarrier technology not only provides a significantly larger surface area per unit 
volume of bioreactor (Nienow 2006) compared to T-flask culture, but also combines the 
potential ease of scalability, flexible modes of operation, process monitoring and control 
capability associated with bioreactor cultures that makes bioreactor culture so 
widespread in the biopharmaceutical industry.  Microcarrier culture is commonly used 
as a large-scale expansion technique for the culture of adherent cells in vaccine 
production and was first described by van Wezel (1967) who used positively charged 
DEAE-Sephadex beads to culture rabbit embryonic skin cells and human embryonic 
lung cells (van Wezel 1967).  However, in vaccine development, the product of interest 
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is usually an attenuated/killed virus, with little or no attention paid to the cell during 
downstream processing.  For cell-based therapies, the basis of the product of interest is 
the cell itself, and therefore the focus is not only on cell expansion but also cell quality   
after harvesting from the bioreactor.  A number of challenges in adapting this 
technology for use in the large-scale expansion of anchorage-dependent stem cells such 
as hMSCs therefore remain.   
 
Human MSCs are a key human stem cell candidate for large-scale culture due to their 
multipotency, relative ease of isolation, self-renewal and proliferative capacity, 
therapeutic efficacy and immunosuppressive properties (Pittenger et al. 1999; Jackson et 
al. 2007).  Human MSCs have been defined by the International Society for Cellular 
Therapy as being plastic adherent, positive for the expression of CD73, CD90 and 
CD105 specific surface antigens, negative for the expression of CD14, CD19, CD34, 
CD45 and HLA-DR specific surface antigens, and possessing the capacity to 
differentiate towards the chondrogenic, adipogenic and osteogenic lineages in vitro 
(Dominici et al. 2006).  With over 120 clinical trials taking place involving the use of 
hMSCs (Trounson et al. 2011), there is now a clear need for the development of 
platform technologies for their large-scale culture which would yield them in sufficient 
quantity and quality.  Studies have taken place investigating the culture of hMSCs on 
microcarriers with a range of commercially available microcarriers being used including 
Cytodex-1 (Frauenschuh et al. 2007; Schop et al. 2008), Cytodex-3 (Hewitt et al. 2011), 
Cultispher-S (Eibes et al. 2010), Cultispher-G (Sun et al. 2010) and SoloHill Plastic 
P102-L (Dos Santos et al. 2011).  However in all the aforementioned studies, the largest 
volume used was no more than 200 mL and it is unclear as to whether samples of 
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microcarrier suspension greater than 2 mL were harvested.  Detachment of cells from 
the microcarrier surface and subsequent retention of cell quality is equally as important 
as cell attachment and proliferation given that the product of interest for cell-based 
therapies is the cells.  Therefore it is of paramount importance to consider cell 
harvesting strategies from the outset so as to ensure a viable, holistic bioprocess. 
 
In this work, hMSCs isolated from bone marrow were cultured in fully controllable 5 L 
bioreactors at a working volume of 2.5 L for a period of 12 days on plastic 
microcarriers.  These microcarriers were selected based on their suitability for the 
culture of hMSCs relative to a number of other microcarriers as identified in previous 
unpublished studies conducted by the authors (data not shown) as well as other groups 
(Dos Santos et al. 2011), in addition to their amenability for good manufacturing 
practise (GMP) bioprocesses, given their xeno-free composition.  Whilst it would be 
possible to control the pH and dO2 levels in the bioreactors, it was decided that this 
investigation would be used to monitor and identify the change in pH and dO2 over the 
course of the culture as there is little work in the literature which identifies the optimal 
pH and dO2 levels for microcarrier hMSC culture.   Online monitoring of pH and dO2 is  
a rarity in hMSC culture (monolayer or microcarrier). Thus being able to shift from an 
unmonitored to an online monitored process with the possibility of control is a 
significant step. Cells were also cultured in duplicate 100 mL spinner flasks in parallel 
to the bioreactors for comparison.   
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1. Materials and Methods 
2.1 hMSC monolayer expansion 
Human MSCs were isolated from bone-marrow aspirate donated by Lonza (Lonza, 
Cologne AG), which had been obtained from a healthy donor after the patient provided 
informed consent. The local Ethical Committee approved the use of the sample for 
research.   Cells from passage 1 were cryopreserved at a density of 2 x 106 cells.mL-1 in 
2 mL of 0.5% human serum albumin (v/v) (Sigma, Germany), 5 mL of 
dimethylsulphoxide (Sigma, Germany) and 93 mL of plasmalyte-A (Baxter, Germany).  
Cells were cultured with Dulbecco’s Modified Eagle Medium (DMEM; Lonza, UK) 
supplemented with 10% (v/v) foetal bovine serum (FBS; Hyclone, Lot# RUF35869) 
and 2 mM ultraglutamine (Lonza, UK).  Cells were grown in monolayer culture at 37oC 
in T-flasks seeded at an initial density of 5000 cells.cm-2 and were placed in a 
humidified CO2 controlled incubator which had air supplemented with 5% CO2.  A 
complete medium exchange was performed after 72 h of culture and cells were 
passaged at day 6 of culture (the usual time found by us for early-stage passage hMSCs 
to reach confluency). On passage, the hMSCs were washed with Ca2+ and Mg2+ free 
phosphate buffered saline (PBS; Lonza, UK) and then incubated for 4 min with trypsin 
(0.25%)/EDTA solution (Lonza, UK) to aid cell detachment from the culture plastic.  
Trypsin was then inactivated by the addition of fresh growth medium equivalent to 3x 
the volume of the trypsin solution used for cell detachment. The cell suspension was 
then centrifuged at 220 g for 3 min at room temperature, the supernatant discarded and 
the remaining pellet re-suspended in an appropriate volume of culture medium. Viable 
cells were counted and an appropriate number of cells were then re-seeded to a fresh T-
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flask.  2 passages were required in order to obtain sufficient cell numbers for seeding of 
the bioreactors and spinner flasks.     
 
2.2 Bioreactor and spinner flask culture 
5 L Biostat B Plus bioreactor (diameter, T = 160 mm) (Sartorius Stedim, UK), equipped 
with a 3-blade 45°-pitch wide blade impeller (diameter, D =70 mm) and 4 vertical 
baffles and a dished base were used, each fitted with dissolved oxygen (dO2), 
temperature and pH probes (Hamilton, Germany) at a working volume of 2.5 L.  The 
bioreactor was operated throughout the culture period without sparging or headspace 
flushing with air, though during the exchange of media additional dissolved oxygen 
entered the bioreactor. pH and dO2 were measured continuously and the temperature 
was controlled via a water jacket at 37°C.  100 mL spinner flasks (diameter, T = 60 
mm) (BellCo, USA) with a magnetic horizontal stir bar and a vertical paddle (diameter, 
D = 50 mm) were used in parallel to the bioreactors.  One cap on each spinner flask was 
left loose to allow for gas exchange.  Spinner flasks were set up on a Bell-EnniumTM 
Compact 5 position magnetic stirrer platform (BellCo, USA), maintained in a 37°C, 
humidified CO2 controlled incubator which had air supplemented with 5% CO2.  All 
glass vessels were siliconized using Sigmacote (Sigma, UK) and left overnight prior to 
autoclaving and rinsing with deionised water.  10,000 cm2 surface area of solid, non-
porous Plastic P-102L microcarriers (Solohill Engineering Inc., US) was used for each 
bioreactor and prepared in accordance with the manufacturer’s specification.  Prior to 
cell inoculation, microcarriers were conditioned with 1 L growth medium for at least 1 
h.  Cells were seeded at a density of 6000 cells.cm-2, which equates to approximately 5 
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cells per microcarrier bead.  A 50% medium exchange was performed at day 3, and then 
every 2 days thereafter.    
Following inoculation, the culture was static for a period of 18 h, after which the culture 
was agitated constantly at NJS (the impeller speed at which the microcarriers were just 
suspended). This speed was selected as it would ensure that all of the cells attached to 
the microcarrier surface would be available for mass transfer of nutrients to them and 
metabolites from them. These transfer rates are very insensitive to agitation speed above 
NJS (Nienow 1997b) but the potential for damage increases rapidly as speed increases 
(Croughan et al. 1987; Nienow 2006). Thus, NJS as the operating speed is an 
appropriate choice. NJS was determined visually for the 3-blade 45°-pitch segment 
impeller and a Rushton turbine impeller with 6 vertical blades.  The impellers had the 
same NJS but the latter has a higher specific energy dissipation rate due to its much 
higher power number (Ibrahim and Nienow 1995). Since higher specific energy 
dissipation rates correlate with a greater potential for cell damage (Croughan et al. 1987; 
Nienow 2006), the down pumping impeller was chosen for the bioreactor culture. The 
choice of this impeller type and its relative size (D/T) fitted in well with an earlier study 
on microcarrier suspension (Ibrahim and Nienow 2004). The actual NJS was 75 rpm for 
the bioreactor, whilst in the spinner flasks it was 30 rpm.  
2.3 Analytical Techniques     
A 1 mL sample was aseptically obtained from both the bioreactors and spinner flasks 
for analysis of pH, [glucose] mmol/L, [lactate] mmol/L, and [ammonium] mmol/L 
using a Nova Bioprofile FLEX bioanalyser (USA).  Cell counting and viability (via 
propidium iodide exclusion) was done using a NucleoCounter NC-100 automatic 
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mammalian cell counter (Chemometec, Denmark).  Samples for cell counting were 
determined whilst the cells were still attached to the microcarrier.    Based on the viable 
cell number and metabolite data, the following parameters were determined: 
1. Specific Growth Rate: 𝜇 = �𝐿𝑛 �𝐶𝑥(𝑡)/ 𝐶𝑥(0)��
∆𝑡
 
 
Where µ = specific growth rate (h-1), Cx(t) and Cx(0) = cell numbers at the end and start 
of exponential growth phase respectively and t = time (h)  
2. Doubling time:  𝑡𝑑 = 𝐿𝑛 2𝜇  
 
Where td = doubling time (h) and µ = specific growth rate (h-1) 
3. Fold Increase  = 𝐶𝑥(𝑓)
𝐶𝑥(0) 
 
where Cx(f) = maximum cell number and Cx(0) = initial cell number 
4. Specific metabolite consumption rate:  𝑞𝑚𝑒𝑡 = 𝜇𝐶𝑥(0)  ×  𝐶𝑚𝑒𝑡 (𝑡) −  𝐶𝑚𝑒𝑡 (0)𝑒𝜇𝑡− 1  
 
where qmet = specific metabolite consumption rate, µ = specific growth rate (h-1), Cmet(t) 
and Cmet(0) = concentration of metabolite at the start and end of exponential growth 
phase respectively, Cx(0) = cell number at the start of exponential growth phase and t = 
time (h)  
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5. Lactate yield from glucose: 𝑌𝐿𝑎𝑐/𝐺𝑙𝑐 = ∆[𝐿𝑎𝑐]∆[𝐺𝑙𝑐] 
where YLac/Glc = lactate yield from glucose, ∆[Lac] = lactate production over specific 
time period and ∆[Glc] = glucose consumption over same time period 
2.4 Harvesting 
At day 8 of the culture, 60 mL was obtained from each bioreactor and placed into fresh 
100 mL spinner flasks.  The microcarriers were allowed to settle after which the 
medium was aspirated.  The microcarriers were then washed with Ca2+ and Mg2+ free 
PBS and 60 mL trypsin (0.25%)/EDTA was added and spinner flasks were placed in a 
humidified CO2 controlled incubator for 7 min.  Whilst incubating and based on studies 
of particle abrasion (Nienow and Conti, 1978), the vessels were agitated briefly at 150 
rpm to aid detachment.  After incubation, the cells were quenched with 70 mL growth 
medium and vacuum filtered using a Steriflip® 60 µm filtration unit (Millipore, UK).  
The cell suspension was then centrifuged at 220 g for 5 min and resuspended in growth 
medium.  Cell viability was determined using the NucleoCounter NC-100.      
1.5 Cell characterisation 
1.5.1 Immunophenotypic analysis 
Immunophenotypic analysis of the hMSCs was determined by flow cytometry before 
expansion on the microcarriers and on the cells after harvesting.  This was performed 
using a Beckman Coulter Quanta SC flow cytometer (Beckman Coulter, UK) with 
excitation at 488nm.  Cells were prepared for analysis by centrifuging at 300 g.  The 
supernatant was discarded and the cells were resuspended in flow cytometry stain buffer 
(R&D Systems, UK).  A panel of mouse anti-human monoclonal antibodies was used to 
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target cell-surface receptors and was prepared in accordance with the manufacturer’s 
instructions.  The antibodies were based on the panel recommended by the ISCT 
(Dominici et al. 2006) and included CD73-PE, CD90-PE CD105-PerCP, CD14 FITC, 
CD19 FITC  CD34-PE-Cy7 CD45-PE-Cy5, and HLA-DR-FITC (BD Biosciences, UK; 
R&D Systems, UK).  Cells were incubated with the antibody in the dark at room 
temperature for 30 min.  Associated isotype controls were also prepared for all 
experimental conditions.  A minimum of 10 000 events were recorded for each sample 
and the data was analysed using FlowJo computer software (Treestar Inc, USA). 
 
1.5.2 Differentiation capacity 
The multi-lineage potential of the cells was ascertained by inducing the samples post-
expansion with the StemPro Adipogenesis kit, StemPro Chondrogenesis kit and 
StemPro Osteogenesis kit (Life Technologies, UK).  The differentiation media were 
prepared as per the manufacturer’s instruction.  Briefly, this involved thawing the 
supplement overnight and adding to the basal differentiation medium.   
 
Chondrogenic differentiation involved the formation of a micromass of hMSCs, 
generated by seeding 5 µL of a cell suspension which was at a density of 1.6 x 107 
cells.mL-1 into a microwell plate.  The microwell plate was placed into the incubator for 
2 h, after which 1 mL chondrogenic differentiation medium was added; the cells were 
then returned to the incubator.  Cells undergoing adipogenic and osteogenic 
differentiation were seeded onto separate microwell plates at a cell density of 5000 
cells.cm2 in growth medium and left in a humidified incubator at 37 °C, 5 % CO2 for 3 
days.  The growth medium was then replaced with either adipogenic or osteogenic 
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differentiation medium and returned to the incubator.  The differentiation medium for 
each differentiation assay was replaced every 72 h until day 21, at which point the 
hMSCs undergoing osteogenesis were stained with alkaline phosphatase (ALP) and 
Von Kossa stains and those undergoing chondrogenic differentiation were stained with 
Alcian Blue.   
 
For chondrogenic differentiation, after fixing the cells with 2% (v/v) paraformaldehyde 
(PFA) for 30 min at room temperature, cells were washed three times with Ca2+ and 
Mg2+ free PBS and 1% (w/v) Alcian Blue (chondrogenic) solution was added and 
incubated at room temperature for 60 min.  Prior to observing under the microscope, the 
samples were washed with PBS three times and 1 mL distilled water was added.  Upon 
final washing, the samples were observed under a Nikon TS-100 light microscope 
(Nikon, UK). 
 
For osteogenic differentiation, the cells were fixed with 10% cold neutral-buffered 
formalin for 20 min at room temperature.  Samples were then washed with Ca2+ and 
Mg2+ free PBS and kept in distilled water for 15 min at room temperature before 
incubating with 4% (v/v) Napthol AS-MX phosphate alkaline solution in a darkened at 
room temperature for 45 min.  Prior to observing under a microscope, samples were 
washed three times with distilled water.  Distilled water was then removed and samples 
incubated with 2.5% (v/v) silver nitrate solution for 30 min at room temperature.  The 
samples were then washed with distilled water three times before observing under the 
Nikon light microscope. 
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1.5.3 Plastic-adherence and cell morphology   
For plastic adherence and morphology cells obtained after harvesting were seeded into 
T-25 flasks to determine their ability to attach to tissue culture plastic as well as to 
qualitatively identify any morphological changes to the cells post-harvest.  The cells 
were observed using the Nikon light microscope mentioned previously. 
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2. Results and Discussion 
3.1 hMSC growth 
The expansion of hMSCs on microcarriers in a stirred-tank bioreactor at the litre-scale 
was achieved over a period of 12 days. In parallel to the bioreactor study, hMSCs were 
also cultured in 100 ml spinner flasks at the same cell seeding density to surface area 
ratio.  The microcarrier seeding density chosen, 6000 cells.cm-2, equates to ~ 5 
cells/bead.  This was chosen based on preliminary work (Hewitt et al. 2011) and for 
comparability with standard T-flask culture where the seeding density used is typically 
5000 cells.cm-2. In all cases reproducible results were obtained (Figure 1 and Figure 2). 
In the 2 bioreactors, the maximum cell densities achieved were 1.68 x 105 cells/ml and 
1.44 x 105 cells/ml by day 9. During this time, the dO2, though not controlled, never fell 
below 45% of saturation, well above the level of 20% where previous work with these 
cells had shown a deterioration in performance ((Rafiq et al. 2013). Operating in this 
way and knowing the cell density as a function of time enabled an estimate of the 
specific oxygen uptake rate of the cells to be calculeated, the average value being ~ 8.1 
fmol/cell h for bioreactor 1 and ~ 6.3 fmol/cell h for bioreactor 2.   
The cell density achieved was similar to the maximum of 1.10 x 105 cells/ml and 1.50 x 
105 cells/ml achieved in the 2 spinner flasks. However, it is notable that growth in the 
spinner flasks was slower than that in the bioreactors as the maximum cell densities in 
the latter were not reached until day 10.  This is also reflected in the maximum specific 
growth rates and doubling times, 0.014 h-1 and ~ 80 h for the bioreactors and 0.006-
0.013 h-1 and ~ 100-130 h for the spinner flasks respectively (Table 1).  The doubling 
times are noticeably longer than those calculated for the same hMSCs in T-flask culture 
14 
 
which are typically 45-60 h depending on the medium exchange strategy used, if 
cultured at 37°C under conditions of 100% dO2 (Rafiq et al. 2013; Schop et al. 2009) 
Based on the maximum cell densities achieved, a greater than 6-fold expansion of the 
hMSCs in the bioreactors was realised, which is comparable to that from standard T-
flask culture (ranging from 5-10 fold depending on the medium exchange strategy used, 
if cultured at 37°C under conditions of 100% dO2 (Rafiq et al. 2013)).  The number of 
cells obtained from the 5 L bioreactors is equivalent to 55 - 65 confluent T-175 tissue 
culture flasks (where confluence for a T-175 for this hMSC cell line is approximately 
6.5 x 106 cells.  A slightly lower fold expansion was achieved in both spinner flasks 
(3.66 and 5 for spinner flasks 1 and 2, respectively).  
 
The metabolite profile for both the bioreactor and spinner flask cultures correlates well 
with the respective growth curves (Figures 1b and 2b), with increasing cell numbers 
resulting in a greater concentration of lactate and ammonium measured in the medium 
with a concomitant decrease in the concentration of glucose.  The level of glucose 
decreases steadily during the initial stages in both culture systems and subsequently 
begins to decrease rapidly until cells reach their maximum cell densities (e.g. days 8 and 
9 for the bioreactors) and reaches levels < 1 mmol/L.  However immediately after a 
medium exchange, there is a measurable increase in the level of glucose and a decrease 
in the levels of lactate and ammonium as identified by the spikes at days 3, 5, 7, 9 and 
11 (Figure 1b and 2b).  In both culture systems, the level of lactate does not begin to 
increase until after day 6, where for example with the bioreactors, it rises from ~5.5 
mmol/L, to ~ 10 mmol/L by day 11. Although similar trends are seen for both 
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bioreactors and spinner flasks, it is notable that in both spinner flasks, a higher lactate 
and ammonium concentration was measured at the end of the culture (~ 12 mmol/L 
lactate, 1.1 mmol/L ammonium) than for the bioreactors (~ 10 mmol/L lactate, 0.5 
mmol/L ammonium). It is thought that this is not simply to do with differences in cell 
yields but probably due to a difference in the culture environments and this will be 
further explored below.  However, in neither culture system do they reach growth 
inhibitory levels for hMSCs, which have been determined experimentally to be 
approximately > 20 mmol/L and > 2 mmol/L for lactate and ammonium respectively 
(Schop et al. 2009).  Therefore, whilst the accumulation of these waste products can 
lead to detrimental effects on hMSC growth, it is more likely that glucose limitation was 
a major factor here. This suggestion is supported by the fact that glucose is considered 
the primary source for ATP through either oxidative phosphorylation (resulting in 30-38 
moles of ATP for each molecule of glucose) or anaerobic glycolysis (resulting in 2 
moles of ATP and 2 moles of lactate for each molecule of glucose). Thus, its presence is 
fundamental to cell proliferative capacity (Glacken 1988).   
 
Analysis of the specific production and utilisation of lactate compared to glucose is 
interesting (Figure 3).  In all cases, between days 9 and 12, the amount of lactate 
produced when compared to glucose consumed rises above 2 mol. mol-1, which is the 
maximum theoretical yield of lactate from glucose (Glacken 1988). This observation 
suggests that another carbon source, most likely glutamine, is also being consumed 
which, when metabolised, degrades into lactate and ammonium (amongst other 
metabolites), hence resulting in higher lactate yields with a concomitant increase in 
ammonium concentration. The fact that this occurs earlier (day 9) for the bioreactors 
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than for the spinner flasks (day 10 – 11) reflects the shorter doubling time, maximum 
specific growth rates and higher fold increase in the former (Table 1).  
 
Whilst the lack of glucose is one factor that is likely to impact cell expansion, it is also 
important to consider other factors.  A significant advantage of culturing cells in a 
bioreactor system, as opposed to traditional monolayer culture in T-flasks or roller 
bottles, is the ability of online monitoring and control of various critical culture 
parameters, such as pH and dO2.  Whilst the dO2 and pH were not directly controlled 
here, these parameters were monitored throughout the course of the bioreactor cultures 
(Figure 1c). The measurement of these parameters was not possible in the spinner flasks 
used in this work. As expected, there is a gradual decrease in both the pH and dO2 as 
the culture conditions become more acidic as a result of lactate accumulation, and 
decrease in dO2 as the cells consume oxygen.  Previous work has demonstrated that 
with this cell line, there is a significant decrease in cell yield in monolayer culture 
conditions when grown under 20% dO2 in comparison to 100% dO2 (Rafiq et al. 2013) 
with an associated increase in both the glucose consumption and lactate production 
rates.  After 12 days in culture the dO2 for both bioreactors reaches approximately 50%.  
The decreasing oxygen levels in the medium may be a contributory factor in the 
inhibition of hMSC expansion as was found in the monolayer culture of this hMSC line 
under lower oxygen conditions (Rafiq et al. 2013).  Likewise, the specific glucose 
consumption and lactate production rates (Figure 4) increase in both bioreactors towards 
the end of the culture (after day 9) when the oxygen level is lower, similar to the trend 
found previously in monolayer culture (Rafiq et al. 2013).  It was thought that in the 
monoculture case that despite the lower cell number, the lower dO2 levels caused the 
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cells to become quiescent (with respect to expansion), whilst still being metabolically 
active so as to adapt to the culture conditions.  It is possible that this could also be 
occurring in the bioreactor when the oxygen level in the culture medium starts to 
decrease, resulting in an increase in the glucose consumption and lactate production rate 
towards the end of the culture, despite there being fewer cells.   
As well as the oxygen concentration, pH is also a critical culture parameter. The pH in 
both bioreactors is initially ~7.2 but it steadily falls throughout the course of the culture 
to become increasingly acidic, reaching pH values of approximately 6.9 and 6.7 for 
bioreactors 1 and 2 respectively.  This drop demonstrates that despite regularly 
refreshing the medium, which utilises a sodium biocarbonate buffer system, the culture 
conditions still become acidic as a result of lactic acid production and accumulation.  
This change results in a deviation from the physiological pH and therefore could also 
have an impact on cell growth.  
In addition to the possibility that the medium culture conditions resulted in hMSC 
growth inhibition, another potential limiting factor is that of surface area.  It was 
calculated that by day 9, the cells had achieved theoretical confluency of ~ 27 
cells/microcarrier (based on equivalent monolayer culture confluence) and additional 
microcarriers were not added at any point during the culture. As a result, assuming 
confluence was achieved towards the end of the rapid growth phase, it is highly likely 
that this condition, in combination with the previously aforementioned factors (glucose 
limitations, decrease in pH and dO2) resulted in the culture entering the stationary/death 
phase after day 9.   
 
18 
 
The fact that the growth at the 5 L scale, a larger scale than previously reported in the 
open literature, is somewhat better than in the spinner flask is clearly encouraging. It is 
interesting to consider whether this improvement can be explained by the different 
physical environment in the two cases. This difference is not only due to the potential 
for more precise measurement in the bioreactor, which showed that the dO2 never fell 
close to the level (20%) at which a poorer performance had been observed in T-flasks 
((Rafiq et al. 2013); and the fall in pH was not to an unacceptable level. It is also 
inherent in the different geometries and scales of the two. Firstly, in the spinner flask, 
the spinner is essentially a rather crude radial flow impeller whilst in the bioreactor, a 
down pumping axial flow impeller is used and it is well established that the latter 
require much less energy to suspend particles such as microcarriers (Ibrahim and 
Nienow 1996, 1999) In addition, the lack of baffles in the spinner flask compared to the 
bioreactor, even when the microcarriers are in motion, generally leads to a much less 
evenly distributed suspension with the particles concentrating in the lowest part of the 
flask (Nienow 1997a). Thus, it is possible that the poorer particle suspension 
characteristics of the spinner flask are impacting negatively on cell growth. Another 
important parameter that changes across the scales as well as with geometry is the 
quality of homogenisation. This parameter generally deteriorates on scale-up but it is 
also much poorer in the absence of baffles (Nienow 2006). This improved homogeneity 
due to baffling will become more important when pH is controlled by the addition of 
base and with increasing scale.  
Thus, though at this stage it is not possible to give a precise explanation for the 
improvement from the spinner flasks to stirred bioreactor, the changes in these different 
parameters with geometrical configuration and scale are encouraging in relation to the 
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greater scale up that will be required for commercial production of cells for allogeneic 
thereapies (Want et al, 2012). 
3.2 Cell Harvest 
Whilst there is a clear need for the optimal attachment and proliferation of hMSCs, 
equally as important is the ability to successfully harvest hMSCs of sufficient quantity 
and quality.  Using a novel and scalable harvesting strategy based on earlier literature 
on particle abrasion (Nienow and Conti 1978), cells were harvested from the 
microcarriers in 60 ml of the bioreactor culture (indeed we have now successfully 
scaled this up to 500 ml (data not shown)).  By trypsinizing and agitating at a higher 
agitator speed in a separate vessel (for details refer to Section 2.4), the cells successfully 
detached from the microcarriers (Figure 5).  Then, using the Steriflip® 60 µm filtration 
unit, the cells were filtered from the microcarriers and subsequently centrifuged.  60 ml 
samples were taken from each bioreactor after day 8 and after harvest, the total cell 
number from the 60 ml matched with the viable cells/ml value obtained via the day 8 
sample based on the NucleoCount measurement, thereby validating the daily sampling 
and counting method.     
3.3 Cell Quality 
In order to determine the quality of the hMSCs and to identify whether there had been 
any change following microcarrier expansion in a bioreactor and the subsequent harvest, 
the cells were analysed according to the Dominici panel of markers (Dominici et al. 
2006) to ascertain their immunophenotypic expression as well as tissue-culture 
adherence and morphology (both pre-inoculation and post-harvest) and for their 
multilineage differentiation potential.   
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For both bioreactors (Table 2), both pre-inoculation and post-harvest, >99% of the cell 
population were positive for CD73, CD90 and CD105, whilst for the negative markers 
CD14, CD19, CD34 and HLA-DR, <2% of the cell population was positive for these 
markers pre-inoculation, and this reduced even further to <1% post-harvest.  Crucially, 
this set of data demonstrates that the immunophenotype of hMSCs are not affected by 
either the upstream or downstream processing, often a concern that cells will be 
sensitive to bioprocessing.     
In all cases. hMSCs were able to adhere and grow on tissue culture plastic post-harvest 
whilst retaining their key morphological features, demonstrating similar morphology 
both before and after bioreactor culture (Figure 6).  The multilineage differentiation 
potential of the cells was investigated post-harvest by inducing the hMSCs to 
differentiate towards the adipogenic, chondrogenic and osteogenic lineages.  After 21 
days in lineage-specific differentiation media, samples of all experimental conditions 
were found to be positive for alkaline phosphatase and von Kossa staining 
demonstrating osteogenic differentiation capability; positive for adipogenic 
differentiation through the clear formation of lipid vacuoles, and positive for Alcian 
Blue staining demonstrating chondrogenic differentiation capability (Figure 7).  
Therefore, the microcarrier bioreactor culture and subsequent harvest of hMSCs had no 
impact on the ability of the cells to retain their differentiation capacity.  As such, the 
characterisation analyses have demonstrated that hMSCs have retained key quality 
attributes (identity and function – where function is linked to differentiation capacity) 
after large-scale bioprocessing.   
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3. Conclusions 
The successful bioprocessing of human mesenchymal stem cells is not trivial. Indeed, 
expanding human stem cells in culture has been more of an art than a science, so much 
so that some laboratories do not grow human stem cells at all. Regenerative medicine 
promises to revolutionise clinical practise and the realisation of this promise requires 
the development of scalable growth and harvest strategies for the larger scale production 
of fully functional human stem cells. Here we report for the first time the successful 
growth of bone-marrow derived hMSCs in fully controllable 5 L bioreactors at a 
working volume of 2.5 L for a period of 12 days on plastic microcarriers.  Moreover, a 
scalable harvesting strategy was developed to successfully detach a large volume of 
cells from the cell-microcarrier suspension, thus outlining the potential for the 
successful harvesting of large volumes of cells from microcarriers.  Importantly, the 
bioprocessing unit operations had little effect, if any, on the quality of the cells for 
specific regenerative medicine purposes. It is believed that this is the first instance in 
which both the successful hMSC cell growth on microcarriers coupled with a 
detachment protocol from them for subsequent downstream processing at the litre scale 
has been reported in a peer-reviewed journal. However, it is recognised that the 
productivity of even the best bioreactor run, equivalent to that produced manually from 
65 confluent T-175 flasks was insufficient to meet the demand for the high numbers of 
cells required for a single cell-based therapy. Nevertheless the results are promising 
given the opportunity for further optimisation of the culture conditions including feed 
strategy (e.g. perfusion) and the harvesting step as well as the advantage of scalability 
and online control with a fully instrumented bioreactor system. Importantly, the 
improved performance in the 5L baffled bioreactors compared to the spinner flasks is 
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particularly encouraging because such configurations are the easiest to scale-up 
(Nienow 2006), and there are physical studies of reactors and bioreactors in the 
literature to suggest that further increases in scale with such geometries are likely to be 
successful.    
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Table 1 Fold increase, doubling time and maximum specific growth rate in each of the 
vessels 
 
 
 
 
 
  Bioreactor 1 Bioreactor 2 Spinner flask 1 Spinner flask 2 
Fold Increase 7.02 6.02 3.66 5.00 
Doubling time (h) 76.8 83.4 128.0 103.4 
Max specific growth rate (h
-1
) 0.014 0.014 0.006 0.013 
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Table 2 Immunophenotypic expression of hMSCs before and after bioreactor culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Pre-inoculation (Day 0) Post-bioreactor harvest (Day 13) 
CD90 (+ve) 99.9 ± 0.1 99.7 ± 0.2 
CD73 (+ve) 99.9 ± 0.0 99.9 ± 0.0 
CD105 (+ve) 99.9 ± 0.1 99.9 ± 0.05 
CD14 (-ve) 0.17 ± 0.01 0.35 ± 0.1 
CD19 (-ve) 0.36 ± 0.004 0.79 ± 0.02 
CD34 (-ve) 1.12 ± 0.15 0.1 ± 0.02 
CD45 (-ve) 0.49 ± 0.03 1.71 ± 0.07 
HLA-DR (-ve) 0.49 ± 0.05 0.962 ± 0.04 
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Figure 1: The growth of hMSCs in 5 L bioreactor vessels over 12 days. A) Viable 
cells/ml readings for bioreactor 1 (left) and bioreactor 2 (right), B) nutrient and 
metabolite concentrations for bioreactor 1 (left) and bioreactor 2 (right), C) pH and dO2 
readings for bioreactor 1 (left) and bioreactor 2 (right). 
 
Figure 2: The growth of hMSCs in 100 ml spinner flasks over 12 days. A) Viable 
cells/ml readings for spinner flask 1 (left) and spinner flask 2 (right), B) nutrient and 
metabolite concentrations for spinner flask 1 (left) and spinner flask 2 (right). 
 
 Figure 3: Yields of lactate from glucose for each vessel with readings from days 9 to 12. 
Reference point at 2 mol mol-1 as this is the maximum theoretical yield of lactate from 
glucose. 
 
Figure 4: Specific growth, glucose consumption and lactate production rates for 
bioreactor 1 (A) and bioreactor 2 (B) over 12 days. 
 
Figure 5: Images of hMSCs which have been successfully detached from the 
microcarrier surface after harvesting. A) Plastic P102-L microcarrier bead, B) harvested 
hMSCs. 
 
Figure 6: hMSC morphology when cultured on tissue culture plastic before inoculation 
(left) and after harvesting (right). 
 
Figure 7: Differentiation potential of hMSCs after harvesting down the adipogenic (left), 
osteogenic (centre) and chondrogenic (right) lineages. 
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